FDA Nears Target Goal For Voluntary Genomic Data Submissions
FDA expects to reach its annual target of 20 submissions for the first time since the Voluntary Genomic Data Submission program began in 2005
You may also be interested in...
Three years into FDA's Voluntary Genomic Data Submission program, companies are more comfortable with the agency's ability to separate the review of the voluntary data from regulatory actions, according to FDA Associate Director of Genomics Felix Freuh
FDA's final pharmacogenomics guidance outlines the benefits of voluntary pharmaceutical industry submissions of genomic data to the agency
Electronic clinical trial databases under development at FDA's Office of Women's Health will help sponsors design trials that account for gender and other demographic differences among patients, FDA Commissioner McClellan said